Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

AGE-RELATED CHANGES IN HEMATOPOIESIS

Descrizione del progetto

Grazie a nuova linfa, la ricerca affronterà le malattie del sangue nell’invecchiamento

Il sangue svolge funzioni fondamentali, tra cui trasporto di gas e sostanze nutritive, regolazione della temperatura e del pH, coagulazione del sangue e risposta immunitaria. Eventuali disfunzioni nell’ematopoiesi (il processo attraverso il quale si formano le cellule del sangue) possono avere effetti dannosi di vasta portata. Con l’avanzare dell’età, questo processo cambia naturalmente. Cambiamenti possono tuttavia essere associati anche allo sviluppo di malattie ematologiche, tra cui l’anemia e alcuni tumori. Il progetto ARCH, finanziato dall’UE, sta formando una coorte di giovani scienziati per studiare il potenziale legame tra i cambiamenti nel sistema ematopoietico legati all’età e l’emergenza di malattie. Si prevede che i loro contributi avranno un impatto sui risultati dei pazienti, sull’onere sul sistema sanitario e sulla competitività dell’UE in questo campo.

Obiettivo

ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.

Coordinatore

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
Contribution nette de l'UE
€ 261 499,68
Indirizzo
PIAZZA DELL'ATENEO NUOVO 1
20126 MILANO
Italia

Mostra sulla mappa

Regione
Nord-Ovest Lombardia Milano
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 261 499,68

Partecipanti (14)

Partner (4)